Based on its activities in different countries in Africa, the EuResist Network has promoted the EuResist - Africa Network devoted to the study of resistance to HIV drugs in Africa.
The EuResist Africa Network is on a volunteer basis and is open to new partners.
Please contact us if you are interested to participate.
At the end of 2016, the EuResist Africa Network launched an observational, retrospective, multicenter, multinational study to analyse the features of second-line ART failure in SSA.
Objectives of the study are:
to describe the characteristics and the determinants of virological failure to second-line ART in Sub-Saharan African adult (age >=18 y.o.) patients
to calculate the incidence of second-line failure
to identify causes of second-line treatment failure
- Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
- Infectious Diseases Institute, Kampala, Uganda
- Arsi University, Asella, Ethiopia
- Heinrich Heine University Düsseldorf, Germany
- EuResist Network
Data have been collected from 2255 patients who started second line therapy at the involved sites.
Results will be presented at the INTERNATIONAL WORKSHOP ON HIV DRUG RESISTANCE AND TREATMENT STRATEGIES 6-8 November 2017 in Johannesburg with oral and poster presentations:
Effectiveness of Protease-Inhibitor-based Second line Antiretroviral Therapy in sub-Saharan Africa.
Authors: F. S. Sarfo, B. Castelnuovo, I. Fanti, T. Feldt, F. Incardona, R. Kaiser, I. Lwanga, G. Marrone, A. Sönnerborg, Tafese B. Tufa, M. Zazzi, A. De Luca for the EuResist Africa Network